We decided to stratify patients carrying CFHR5 variations into a separate group in order to have a homogeneous group of MPGN patients with wild-type FHR-5 that facilitates better understanding of the association and relevance of FHR-5 protein levels with clinical features and development of end-stage renal disease (ESRD). Here, CFHR5 is linked to stage 5 chronic kidney disease.